156 related articles for article (PubMed ID: 27093451)
21. Combination of MUC5ac and WT-1 immunohistochemistry is useful in distinguishing pancreatic ductal carcinoma from ovarian serous carcinoma in effusion cytology.
Han L; Pansare V; Al-Abbadi M; Husain M; Feng J
Diagn Cytopathol; 2010 May; 38(5):333-6. PubMed ID: 19856421
[TBL] [Abstract][Full Text] [Related]
22. Evaluation of the diagnostic ability of laminin gene family for pancreatic ductal adenocarcinoma.
Yang C; Liu Z; Zeng X; Wu Q; Liao X; Wang X; Han C; Yu T; Zhu G; Qin W; Peng T
Aging (Albany NY); 2019 Jun; 11(11):3679-3703. PubMed ID: 31182680
[TBL] [Abstract][Full Text] [Related]
23. Cytoplasmic TRAIL-R1 is a positive prognostic marker in PDAC.
Gundlach JP; Hauser C; Schlegel FM; Böger C; Röder C; Röcken C; Becker T; Egberts JH; Kalthoff H; Trauzold A
BMC Cancer; 2018 Jul; 18(1):777. PubMed ID: 30064384
[TBL] [Abstract][Full Text] [Related]
24. PROX1 and β-catenin are prognostic markers in pancreatic ductal adenocarcinoma.
Saukkonen K; Hagström J; Mustonen H; Juuti A; Nordling S; Kallio P; Alitalo K; Seppänen H; Haglund C
BMC Cancer; 2016 Jul; 16():472. PubMed ID: 27411302
[TBL] [Abstract][Full Text] [Related]
25. Loss of heterozygosity status of D9S105 marker is associated with downregulation of Krüppel-like factor 4 expression in pancreatic ductal adenocarcinoma and pancreatic intraepithelial lesions.
Funel N; Morelli M; Giovannetti E; Del Chiaro M; Pollina LE; Mosca F; Boggi U; Cavazzana A; Campani D
Pancreatology; 2011; 11(1):30-42. PubMed ID: 21412023
[TBL] [Abstract][Full Text] [Related]
26. Validation of biomarkers that complement CA19.9 in detecting early pancreatic cancer.
Chan A; Prassas I; Dimitromanolakis A; Brand RE; Serra S; Diamandis EP; Blasutig IM
Clin Cancer Res; 2014 Nov; 20(22):5787-95. PubMed ID: 25239611
[TBL] [Abstract][Full Text] [Related]
27. Preoperative CEA and CA 19-9 are prognostic markers for survival after curative resection for ductal adenocarcinoma of the pancreas - a retrospective tumor marker prognostic study.
Distler M; Pilarsky E; Kersting S; Grützmann R
Int J Surg; 2013; 11(10):1067-72. PubMed ID: 24161419
[TBL] [Abstract][Full Text] [Related]
28. aPKCλ/ι is a beneficial prognostic marker for pancreatic neoplasms.
Kato S; Akimoto K; Nagashima Y; Ishiguro H; Kubota K; Kobayashi N; Hosono K; Watanabe S; Sekino Y; Sato T; Sasaki K; Nakaigawa N; Kubota Y; Inayama Y; Endo I; Ohno S; Maeda S; Nakajima A
Pancreatology; 2013; 13(4):360-8. PubMed ID: 23890134
[TBL] [Abstract][Full Text] [Related]
29. Postoperative serum CEA and CA125 levels are supplementary to perioperative CA19-9 levels in predicting operative outcomes of pancreatic ductal adenocarcinoma.
Xu HX; Liu L; Xiang JF; Wang WQ; Qi ZH; Wu CT; Liu C; Long J; Xu J; Ni QX; Yu XJ
Surgery; 2017 Feb; 161(2):373-384. PubMed ID: 27838102
[TBL] [Abstract][Full Text] [Related]
30. CXCR4--A Prognostic and Clinicopathological Biomarker for Pancreatic Ductal Adenocarcinoma: A Meta-Analysis.
Krieg A; Riemer JC; Telan LA; Gabbert HE; Knoefel WT
PLoS One; 2015; 10(6):e0130192. PubMed ID: 26091099
[TBL] [Abstract][Full Text] [Related]
31. Expression of urocortin in pancreatic ductal adenocarcinoma and pancreatic intraepithelial neoplasia.
Cheng MF; Tsai WC; Hsia KT; Yang YS; Jin JS
APMIS; 2014 Feb; 122(2):147-54. PubMed ID: 23755913
[TBL] [Abstract][Full Text] [Related]
32. Decreased TIP30 expression predicts poor prognosis in pancreatic cancer patients.
Guo S; Jing W; Hu X; Zhou X; Liu L; Zhu M; Yin F; Chen R; Zhao J; Guo Y
Int J Cancer; 2014 Mar; 134(6):1369-78. PubMed ID: 24037692
[TBL] [Abstract][Full Text] [Related]
33. Claudin-4 expression predicts survival in pancreatic ductal adenocarcinoma.
Tsutsumi K; Sato N; Tanabe R; Mizumoto K; Morimatsu K; Kayashima T; Fujita H; Ohuchida K; Ohtsuka T; Takahata S; Nakamura M; Tanaka M
Ann Surg Oncol; 2012 Jul; 19 Suppl 3():S491-9. PubMed ID: 21837532
[TBL] [Abstract][Full Text] [Related]
34. Integrated expression profiling of potassium channels identifys KCNN4 as a prognostic biomarker of pancreatic cancer.
Jiang S; Zhu L; Yang J; Hu L; Gu J; Xing X; Sun Y; Zhang Z
Biochem Biophys Res Commun; 2017 Dec; 494(1-2):113-119. PubMed ID: 29050937
[TBL] [Abstract][Full Text] [Related]
35. Low RASSF6 expression in pancreatic ductal adenocarcinoma is associated with poor survival.
Ye HL; Li DD; Lin Q; Zhou Y; Zhou QB; Zeng B; Fu ZQ; Gao WC; Liu YM; Chen RW; Li ZH; Chen RF
World J Gastroenterol; 2015 Jun; 21(21):6621-30. PubMed ID: 26074700
[TBL] [Abstract][Full Text] [Related]
36. CA-125, but not galectin-3, complements CA 19-9 for discriminating ductal adenocarcinoma versus non-malignant pancreatic diseases.
Coppin L; Benomar K; Corfiotti F; Cattan S; Renaud F; Lapere C; Leteurtre E; Vantyghem MC; Truant S; Pigny P
Pancreatology; 2016; 16(1):115-20. PubMed ID: 26613889
[TBL] [Abstract][Full Text] [Related]
37. Overexpression of DIXDC1 correlates with enhanced cell growth and poor prognosis in human pancreatic ductal adenocarcinoma.
Li X; Xiao Y; Fan S; Xiao M; Wang X; Zhu X; Chen X; Li C; Zong G; Zhou G; Wan C
Hum Pathol; 2016 Nov; 57():182-192. PubMed ID: 27498060
[TBL] [Abstract][Full Text] [Related]
38. MicroRNAs as diagnostic markers for pancreatic ductal adenocarcinoma and its precursor, pancreatic intraepithelial neoplasm.
Xue Y; Abou Tayoun AN; Abo KM; Pipas JM; Gordon SR; Gardner TB; Barth RJ; Suriawinata AA; Tsongalis GJ
Cancer Genet; 2013 Jun; 206(6):217-21. PubMed ID: 23933230
[TBL] [Abstract][Full Text] [Related]
39. Comparison of ILK and ERP29 expressions in benign and malignant pancreatic lesions and their clinicopathological significances in pancreatic ductal adenocarcinomas.
Zhang K; Yao H; Yang Z; Li D; Yang L; Zou Q; Yuan Y; Miao X
Clin Transl Oncol; 2016 Apr; 18(4):352-9. PubMed ID: 26887611
[TBL] [Abstract][Full Text] [Related]
40. Unraveling the potential of CD8, CD68, and VISTA as diagnostic and prognostic markers in patients with pancreatic ductal adenocarcinoma.
Rezagholizadeh F; Tajik F; Talebi M; Taha SR; Shariat Zadeh M; Farhangnia P; Hosseini HS; Nazari A; Mollazadeh Ghomi S; Kamrani Mousavi SM; Haeri Moghaddam N; Khorramdelazad H; Joghataei MT; Safari E
Front Immunol; 2024; 15():1283364. PubMed ID: 38357542
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
